

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Imricor Medical Systems, Inc.
<b>ARBN</b>	633 106 019

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Mark Tibbles
<b>Date of last notice</b>	30 December 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	31 December 2019

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>- 4,548,981 shares of Class A common stock (equivalent to 4,578,981 CHESS Depositary Interests)</li> <li>- 30,000 CHESS Depositary Interests (equivalent to 30,000 shares of Class A common stock)</li> <li>- 314,900 options with an exercise price of US\$0.52 per share of Class A common stock and an expiry date of 15 March 2029</li> <li>- 100,000 options with an exercise price of US\$0.97585 (USD equivalent to A\$1.45) per share of Class A common stock and an expiry date of 30 August 2029</li> </ul>
<b>Class</b>	See above
<b>Number acquired</b>	2,897 shares of Class A common stock (equivalent to 2,897 CHESS Depositary Interests)
<b>Number disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	N/A – issue of additional shares in correcting a minor error for pre-IPO convertible notes conversion – see ASX Announcement dated 27 December 2019.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>- 4,551,878 shares of Class A common stock (equivalent to 4,551,878 CHESS Depositary Interests)</li> <li>- 30,000 CHESS Depositary Interests (equivalent to 30,000 shares of Class A common stock)</li> <li>- 314,900 options with an exercise price of US\$0.52 per share of Class A common stock and an expiry date of 15 March 2029</li> <li>- 100,000 options with an exercise price of US\$0.97585 (USD equivalent to A\$1.45) per share of Class A common stock and an expiry date of 30 August 2029</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of additional shares in correcting a minor error for pre-IPO convertible notes conversion – see ASX Announcement dated 27 December 2019.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.